Surprise snub by FDA of AcelRx's Zalviso

The FDA surprised nearly everyone by rejecting AcelRx Pharmaceuticals' new drug application (NDA) for its pre-programmed, non-invasive, handheld system Zalviso, which delivers 15mcg per dose as needed of sufentanil, an opioid, allowing hospital patients to self-dose in managing their pain.